Azitra (AZTR) Shares Outstanding (2022 - 2026)
Azitra's (AZTR) quarterly Shares Outstanding (Entity) came in at $16.2 million in Q1 2026, up 619.94% YoY from $2.2 million in Q1 2025, and up 232.25% on a QoQ basis from $4.9 million in Q4 2025.
Azitra (AZTR) Shares Outstanding (2022 - 2026) Analysis & Trends
Azitra (AZTR) has 5 years of Shares Outstanding (Entity) data on file, last reported at $16.2 million in Q1 2026.
- Quarterly Shares Outstanding (Entity) rose 619.94% year-over-year to $16.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $16.2 million (up 619.94% YoY) and the FY2025 annual result came in at $4.9 million, up 757.66% from the prior year.
- Shares Outstanding (Entity) advanced to $16.2 million in Q1 2026, from $4.9 million in the prior quarter.
- In the past five years, Shares Outstanding (Entity) ranged from a high of $16.2 million in Q1 2026 to a low of $5225.0 in Q2 2022.
- A 5-year average of $2.0 million and a median of $122584.5 in 2024 frame the typical range for Shares Outstanding (Entity).
- Annual changes were most pronounced in 2023 — Shares Outstanding (Entity) soared 105.68% — and 2025, when it surged 2126.82%.
- Tracing AZTR's Shares Outstanding (Entity) over 5 years: stood at $5225.0 in 2022, then soared by 563.22% to $34653.0 in 2023, then surged by 1539.8% to $568240.0 in 2024, then jumped by 757.66% to $4.9 million in 2025, then jumped by 232.25% to $16.2 million in 2026.
- The last three Shares Outstanding (Entity) figures came in at $16.2 million (Q1 2026), $4.9 million (Q4 2025), and $4.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 445.06 Mn |
| 10 | Azitra | 2.53 Mn | 2.53 Mn | - | 19.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 15.52 Mn |
| Mar 31, 2026 | 15.52 Mn |
| Dec 31, 2025 | 4.87 Mn |
| Sep 30, 2025 | 4.12 Mn |
| Jun 30, 2025 | 2.44 Mn |
| Mar 31, 2025 | 1.98 Mn |
| Dec 31, 2024 | 568,240.00 |
| Sep 30, 2024 | 873,025.00 |
| Jun 30, 2024 | 144,166.00 |
| Mar 31, 2024 | 101,003.00 |
| Dec 31, 2023 | 34,653.00 |
| Sep 30, 2023 | 60,543.00 |
| Jun 30, 2023 | 10,747.00 |
| Mar 31, 2023 | 5,282.00 |
| Dec 31, 2022 | 5,282.00 |
| Sep 30, 2022 | 5,282.00 |
| Jun 30, 2022 | 5,282.00 |